Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

NCT06591845 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Ziresovir 125 mg
DRUG: Ziresovir 500 mg
DRUG: Placebo
DRUG: Moxifloxacin hydrochloride tablet 400 mg

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.